Trial · NCT03823300
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
NCT03823300, Phase 3, Completed, Hoffmann-La Roche; results first posted 2022-05-04
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE). Trials, record NCT03823300. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03823300
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
- NCT number
- NCT03823300
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 658 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Wet Macular Degeneration
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- First posted
- 2019-01-30
- Last updated
- 2025-07-11
- Other registries' IDs
- eudract:2018-004042-42
- Results first posted
- 2022-05-04
Source ClinicalTrials.gov
Registered outcomes43
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | From Baseline through Week 48 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI. |
| Secondary | Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | From Baseline through Week 60 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI. |
| Secondary | Change From Baseline in BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI. |
| Secondary | Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | Baseline, average of Weeks 40, 44, and 48 | BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI. |
| Secondary | Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | Baseline, average of Weeks 52, 56, and 60 | BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI. |
| Secondary | Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI. |
| Secondary | Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI. |
| Secondary | Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI. |
| Secondary | Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI. |
| Secondary | Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | Baseline, average of Weeks 40, 44, and 48 | Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI. |
1 to 10 of 43Source ClinicalTrials.gov
See all 43 registered outcomesOutcomes43
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | From Baseline through Week 48 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | ETDRS Letters | MEAN |
| SECONDARY | Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | From Baseline through Week 60 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | ETDRS Letters | MEAN |
| SECONDARY | Change From Baseline in BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | ETDRS Letters | MEAN |
| SECONDARY | Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | Baseline, average of Weeks 40, 44, and 48 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48 were included in this analysis. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | Baseline, average of Weeks 52, 56, and 60 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Participants with at least one non-missing, valid assessment at Weeks 52, 56, or 60 were included in this analysis. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At a given timepoint, the number analyzed includes participants with a non-missing, valid assessment at that timepoint. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At a given timepoint, the number analyzed includes participants with a non-missing, valid assessment at that timepoint. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At a given timepoint, the number analyzed includes participants with a non-missing, valid assessment at that timepoint. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. At a given timepoint, the number analyzed includes participants with a non-missing, valid assessment at that timepoint. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | Baseline, average of Weeks 40, 44, and 48 | ITT Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48 were included in this analysis. | Percentage of participants | NUMBER |
1 to 10 of 43Source ClinicalTrials.gov
See all 43 outcomesResults by group927
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | Arm A: Faricimab | 6.6 | 95% Confidence Interval 5.3 to 7.8 | ETDRS Letters | |
| Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 | Arm B: Aflibercept | 6.6 | 95% Confidence Interval 5.3 to 7.8 | ETDRS Letters | |
| Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | Arm A: Faricimab | 6.6 | 95% Confidence Interval 5.3 to 7.9 | ETDRS Letters | |
| Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 | Arm B: Aflibercept | 7.1 | 95% Confidence Interval 5.8 to 8.4 | ETDRS Letters | |
| Change From Baseline in BCVA in the Study Eye Over Time | Arm A: Faricimab | Week 4 | 5.1 | 95% Confidence Interval 4.2 to 5.9 | ETDRS Letters |
| Change From Baseline in BCVA in the Study Eye Over Time | Arm B: Aflibercept | Week 4 | 4.3 | 95% Confidence Interval 3.5 to 5.2 | ETDRS Letters |
| Change From Baseline in BCVA in the Study Eye Over Time | Arm A: Faricimab | Week 8 | 6.0 | 95% Confidence Interval 5.1 to 6.9 | ETDRS Letters |
| Change From Baseline in BCVA in the Study Eye Over Time | Arm B: Aflibercept | Week 8 | 5.8 | 95% Confidence Interval 4.9 to 6.8 | ETDRS Letters |
| Change From Baseline in BCVA in the Study Eye Over Time | Arm A: Faricimab | Week 12 | 7.0 | 95% Confidence Interval 6.1 to 8.0 | ETDRS Letters |
| Change From Baseline in BCVA in the Study Eye Over Time | Arm B: Aflibercept | Week 12 | 6.4 | 95% Confidence Interval 5.4 to 7.4 | ETDRS Letters |
1 to 10 of 927Source ClinicalTrials.gov
See all 927 results by groupParticipant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: Faricimab | 331 | |
| Overall Study | STARTED | Arm B: Aflibercept | 327 | |
| Overall Study | Received at Least One Dose of Study Drug | Arm A: Faricimab | 331 | |
| Overall Study | Received at Least One Dose of Study Drug | Arm B: Aflibercept | 326 | |
| Overall Study | Completed up to Week 48 | Arm A: Faricimab | 321 | |
| Overall Study | Completed up to Week 48 | Arm B: Aflibercept | 309 | |
| Overall Study | COMPLETED | Arm A: Faricimab | 297 | |
| Overall Study | COMPLETED | Arm B: Aflibercept | 273 | |
| Overall Study | NOT COMPLETED | Arm A: Faricimab | 34 | |
| Overall Study | NOT COMPLETED | Arm B: Aflibercept | 54 |
Source ClinicalTrials.gov
Adverse events416
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival haemorrhage | Eye disorders | Arm A: Faricimab | 35 | 331 | 47 |
| other | Conjunctival haemorrhage | Eye disorders | Arm B: Aflibercept | 37 | 326 | 72 |
| other | Neovascular age-related macular degeneration | Eye disorders | Arm A: Faricimab | 80 | 331 | 103 |
| other | Neovascular age-related macular degeneration | Eye disorders | Arm B: Aflibercept | 62 | 326 | 81 |
| other | Nasopharyngitis | Infections and infestations | Arm A: Faricimab | 27 | 331 | 33 |
| other | Nasopharyngitis | Infections and infestations | Arm B: Aflibercept | 22 | 326 | 25 |
| other | Cataract | Eye disorders | Arm A: Faricimab | 38 | 331 | 55 |
| other | Cataract | Eye disorders | Arm B: Aflibercept | 26 | 326 | 38 |
| other | Dry eye | Eye disorders | Arm A: Faricimab | 15 | 331 | 27 |
| other | Dry eye | Eye disorders | Arm B: Aflibercept | 21 | 326 | 37 |
1 to 10 of 416Source ClinicalTrials.gov
See all 416 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: Faricimab | 10 | 331 |
| Total, all-cause mortality | Arm B: Aflibercept | 14 | 326 |
| Total, other adverse events | Arm A: Faricimab | 178 | 331 |
| Total, other adverse events | Arm B: Aflibercept | 165 | 326 |
| Total, serious adverse events | Arm A: Faricimab | 91 | 331 |
| Total, serious adverse events | Arm B: Aflibercept | 101 | 326 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm A: Faricimab vs Arm B: Aflibercept: deaths from any cause | Trial comparisons |
| Arm A: Faricimab vs Arm B: Aflibercept: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03823300
GET https://conductscience.org/api/trials/v1/NCT03823300/registered?page=2